Bhumibol Adulyadej Hospital

Bermuda

更新于：2025-01-23

概览

管线布局

概览

关联

项与 Bhumibol Adulyadej Hospital 相关的临床试验

TCTR20241126003

/ Recruiting临床3期IIT

Using of spot urine sodium as guidance on diuretics treatment compare with standard of care to reduced day of congestion in patients with heart failure hospitalization in Bhumibol Adulyadej Hospital. (Randomized controlled trial)

开始日期2024-07-04

申办/合作机构

Bhumibol Adulyadej Hospital

TCTR20240503001

/ RecruitingN/AIIT

The Structural Change of Fetal Brain Development among Diabetic Mother in Bhumibol Adulyadej Hospital

开始日期2024-04-10

申办/合作机构

Bhumibol Adulyadej Hospital

TCTR20240418005

/ RecruitingN/AIIT

A comparison of fetal thymus size between pregnant women with diabetic and non-diabetic disease

开始日期2024-03-18

申办/合作机构

Bhumibol Adulyadej Hospital

100 项与 Bhumibol Adulyadej Hospital 相关的临床结果

登录后查看更多信息

0 项与 Bhumibol Adulyadej Hospital 相关的专利（医药）

登录后查看更多信息

231

项与 Bhumibol Adulyadej Hospital 相关的文献（医药）

2024-12-31·Annals of Medicine

Web application for assisting non-dermatology physicians in learning and managing patients with common cutaneous adverse drug reactions: a multicenter randomized controlled trial

Article

作者: Mettarikanon, Dichitchai ; Eden, Chime ; Sindhusen, Sasipaka ; Chaisriya, Kannattha ; Inthongpan, Mathat ; Tawanwongsri, Weeratian ; Ameentranon, Nuchsara

BACKGROUNDCutaneous adverse drug reactions (CADRs) remain a challenge for non-dermatologists. Medical-related applications to assist in learning about and managing patients with CADRs are scarce. We aimed to evaluate the efficacy of a web application for non-dermatologists in managing CADRs by comparing the knowledge scores of users and non-users.MATERIALS AND METHODSA multicenter randomized controlled trial was conducted between January 2023 and May 2023. Clinician participants were randomized (1:1) into the application and control groups using a simple randomization method. Knowledge scores between the groups were compared to evaluate the efficacy of the web application, and participants' perspectives on the application were also collected.RESULTSA total of 44 clinician participants were included in the final analysis. The median age was 33.0 years (95% confidence interval (CI) 27.5-35.0) and predominantly female (56.8%). The score in the application group (median, 27.0; 95% CI, 25.0-28.0) was significantly higher than that in the control group (median, 14.0; 95% CI 13.0-17.0) (p < 0.001). There were no differences in scores between the sex groups (p = 0.695), between general practitioners (GPs) and non-GPs (p = 0.93), or among groups with different frequencies of evaluation of patients with CADRs (p = 0.266). In addition, the participants in the application group rated a high level of overall satisfaction.CONCLUSIONThe web application for CADRs is an effective and convenient tool for assisting non-dermatologist physicians in learning and providing initial management with a high level of satisfaction. However, prospective long-term randomized controlled studies are required to confirm the efficacy of this tool.

2024-12-31·Renal Failure

SGLT2 inhibitor dapagliflozin reduces proximal tubular cell damage biomarkers in patients with acute heart failure

Article

作者: Chuasuwan, Anan ; Gojaseni, Pongsathorn ; Wattanakul, Jananya ; Chittinandana, Anutra

Acute heart failure (ahF) is characterized by new-onset or worsening symptoms of heart failure, often leading to hospitalization and mortality.Current treatment options for ahF mainly focus on relieving symptoms and reducing fluid overload, which can have potentially harmful effects on kidney function.Sodium-glucose co-transporter 2 (sGLt2) inhibitors have emerged as a disease-modifying therapy to reduce cardiovascular events and prevent the progression of chronic kidney disease (cKD).In this study, we conducted a randomized controlled trial to investigate the protective effect of sGLt2 inhibitors on proximal tubular cell damage biomarkers (urinary [tIMP-2] x [IGFBP-7]) in patients hospitalized for ahF.The primary objective of this study was to compare the change of urinary [tIMP-2] x [IGFBP-7] in sGLt2 inhibitor addon to standard of care with standard of care alone.Initiation of dapagliflozin significantly decrease urine [tIMP-2] X [IGFBP7] during the first week, that supported the protective effect of sGLt2 inhibitor on renal tubular injury.Thus, we may conclude that sGLt2 inhibitor can improve tubular cell injury in patients hospitalized for acute heart failure since urinary [tIMP-2] x [IGFBP-7] is the biomarker of cell cycle arrest during the early phase of proximal tubular damage.

2024-12-01·Critical Care and Resuscitation

Efficacy and safety of guanfacine in hospitalized patients with delirium: A scoping review

Article

作者: Chaba, Anis ; Phongphithakchai, Atthaphong ; Spano, Sofia ; Hikasa, Yukiko ; Maeda, Akinori ; Bellomo, Rinaldo ; Pattamin, Nuttapol

ObjectiveTo assess current evidence regarding guanfacine use in hospitalized patients with delirium.IntroductionDelirium is a common and important complication of critical illness. Central alpha-2 agonists are often used for symptomatic management. Guanfacine is an enteral central alpha-2 agonist approved for the treatment of attention deficit hyperactivity disorders. However, its use for delirium treatment has not been systematically assessed.Inclusion criteriaAll studies of guanfacine to treat patients with delirium during hospitalization. We excluded reviews, letters, commentaries, correspondence, conference abstracts, expert opinions or editorials.MethodsWe performed a systematic search of the literature using: MEDLINE (Ovid), Embase (Ovid), CENTRAL and SCOPUS (Elsevier) from inception until 29 February, 2024. Two independent reviewers assessed the identified citations and abstracts. Data on study and patient characteristics, as well as efficacy and safety outcomes, were extracted. Efficacy was defined by guanfacine's ability to relieve delirium and improve clinical outcomes, including intensive care unit (ICU) length of stay (LOS), hospital LOS, and mortality. Safety was assessed for hemodynamic stability or other reported side effects.ResultsWe screened 908 articles and included two case reports, one case series, two retrospective descriptive cohorts, and one retrospective analytic cohort. Guanfacine therapy was associated with delirium attenuation and a reduction in the use of sedative agents. Median dosage was 1.5 mg daily, with a median time to delirium improvement of 3 days. However, guanfacine therapy was not associated with decreased ICU or hospital LOS. The most frequently reported adverse events were mild hypotension and bradycardia.ConclusionThere is limited data on the efficacy of guanfacine for the treatment of delirium. However, given its pharmacologic properties and its available safety data, controlled investigations may be justified.

100 项与 Bhumibol Adulyadej Hospital 相关的药物交易

登录后查看更多信息

100 项与 Bhumibol Adulyadej Hospital 相关的转化医学

登录后查看更多信息